microdosing glp 1 for gut health Nutritional priorities to support GLP-1 therapy obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society GLP-1 Genetics: How Genes Affect

[DOI] [PubMed] [Google Scholar] He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M

Higher transparency typically signals stronger quality control processes, including: Verified purity levels (often 99%+ via HPLC analysis) Clearly identified third-party laboratory testing Batch-level traceability and verification codes Consistent and accessible documentation While lower pricing may be attractive, limited transparency can make it difficult to independently confirm product consistency

GLP-1s are usually not recommended for people who: Have severe gastrointestinal issues, such as gastroparesis Have an intolerance or allergy to GLP-1s Are pregnant or breastfeeding Have a personal or family history of rare forms of thyroid cancer called medullary thyroid cancer or multiple endocrine neoplasia type 2 Behavioral health is an important consideration before starting GLP-1 medications

however, most results were obtained via single-center observational and retrospective studies and lack information on confounding factors, such as duration of PPI exposure, antibiotic intake, and dietary patterns

Published May 8, 2024

Since GLP-1 RAs are able to reduce appetite and induce satiety and early post-prandial fullness, their use is associated with a significant weight loss secondary to a reduced caloric intake [24]